Intercytex Group plc (LSE: ICX) the leading developer of regenerative medicine products to restore skin and hair, today announces that positive 6 month follow-up data from two Phase II trials of VAVELTA®, its cell therapy product for damaged skin, were presented at the FACE congress on 28th June, 2008.
